Structural Heart Devices Market

Structural Heart Devices Market Forecast and Outlook by Fact.Mr

• In 2025, the structural heart devices market was valued at USD 15.0 billion.
• Based on Fact.MR analysis, demand for structural heart devices is estimated at USD 16.7 billion in 2026 and projected to reach USD 48.2 billion by 2036.
• Fact.MR projects a CAGR of 11.2% during the forecast period.

Summary of the Structural Heart Devices Market

• Demand Drivers
  • Transcatheter Procedure Growth: Hospitals are increasing minimally invasive cardiac intervention adoption across elderly cardiovascular patient populations. Faster recovery periods support higher structural heart device procedure volume.
  • Aging Population Expansion: Rising geriatric population growth is increasing structural heart disease prevalence across developed and emerging healthcare systems. Higher cardiovascular screening rates support stronger procedure diagnosis volume.
  • Hospital Cardiac Investment: Healthcare systems are increasing investment across specialized cardiac intervention infrastructure and advanced imaging capability. Expanding catheterization laboratory capacity supports higher device adoption.
• Key Segments Analyzed
  • By Product: Transcatheter heart valves account for 40% share in 2026 due to rising minimally invasive cardiac procedure adoption across elderly patient populations.
  • By Procedure: Replacement procedures hold 60% share in 2026 supported by higher transcatheter valve replacement volume across structural heart treatment operations.
  • By Age Group: Geriatrics contributes 50% share in 2026 attributable to stronger structural cardiovascular disorder prevalence across aging patient groups.
  • By Indication: Aortic valve stenosis accounts for 45% share in 2026 due to stronger transcatheter valve replacement concentration across stenosis treatment procedures.
  • By End User: Hospitals hold 55% share in 2026 supported by advanced cardiac surgery infrastructure and higher intervention capacity.
  • By Geography: India is projected to record the highest CAGR at 13.1% through 2036 supported by expanding cardiac intervention infrastructure.
• Analyst Opinion at Fact.MR
  • Shambhu Nath Jha, Principal Consultant at Fact.MR, opines, ‘Structural heart device manufacturers are increasing focus on minimally invasive intervention systems and hospital training capability. Reimbursement expansion and physician adoption will shape long-term procedure growth across emerging healthcare markets.’
• Strategic Implications
  • Structural heart device manufacturers should increase physician training programs across emerging cardiac intervention centers. Faster procedure standardization supports wider hospital adoption.
  • Hospital systems should expand catheterization laboratory capacity across high population cardiovascular treatment regions. Higher intervention volume improves long-term procedural efficiency.
  • Cardiac device distributors should strengthen regional supply capability and post-procedure support infrastructure across Asia Pacific healthcare systems.

The market is projected to create nearly USD 31.5 billion in additional revenue between 2026 and 2036. Growth is supported by rising transcatheter cardiac procedure adoption and expanding cardiovascular disease burden across elderly patient populations. Higher device pricing and limited reimbursement access across lower income healthcare systems constrain faster market penetration.

India is projected to expand at 13.1% CAGR supported by expanding cardiac care infrastructure and rising transcatheter procedure adoption. China records 12.6% CAGR attributable to domestic structural heart device manufacturing expansion and higher hospital intervention volume. The United States is projected to grow at 11.4% CAGR driven by higher transcatheter valve replacement adoption and strong reimbursement coverage. Germany is projected to expand at 10.2% CAGR due to rising minimally invasive cardiac surgery preference. Brazil is expected to register 9.8% CAGR supported by private hospital cardiac intervention investment. Japan is expected to expand at 9.1% CAGR due to rising geriatric cardiovascular treatment demand.

Segmental Analysis

Structural Heart Devices Market Analysis by Product

Based on Fact.MR's structural heart devices market report, consumption of transcatheter heart valves is estimated to hold 40% share in 2026. Hospitals prefer minimally invasive valve replacement systems due to lower recovery periods and reduced surgical complication exposure. The U.S. FDA approved Edwards Lifesciences’ EVOQUE Tricuspid Valve Replacement System for treating patients with severe symptomatic tricuspid regurgitation through a minimally invasive transcatheter procedure. [1] The approval marks a major advancement in structural heart therapy by expanding catheter-based valve replacement options beyond aortic and mitral valve interventions.

• Transcatheter Valve Expansion: Cardiovascular device manufacturers are increasing transcatheter valve deployment across hospital cardiac intervention networks.
• Cardiac Device Innovation: Structural heart technology companies are increasing advanced valve repair and occluder system development across minimally invasive cardiovascular treatment operations.
• Procedure Volume Growth: Hospital cardiac centers are increasing transcatheter intervention capability across aortic stenosis treatment operations.

Structural Heart Devices Market Analysis by Procedure

Replacement procedures account for 60% share due to stronger transcatheter valve replacement demand across structural cardiovascular treatment operations. Hospitals prioritize replacement systems because of wider clinical adoption and reimbursement coverage. Abbott received U.S. FDA approval for its TriClip transcatheter edge-to-edge repair system, the first device approved in the U.S. for minimally invasive treatment of tricuspid regurgitation. [2] The approval strengthens Abbott’s structural heart portfolio by expanding catheter-based valve repair options for patients with severe leaky tricuspid heart valves.

• Valve Replacement Investment: Medtronic expanded transcatheter valve replacement procedure training during 2025 across cardiovascular surgery networks.
• Structural Heart Technology Development: Cardiovascular device manufacturers are increasing minimally invasive intervention technology investment across advanced structural heart treatment systems.
• Hospital Procedure Expansion: Cardiac hospitals are increasing replacement procedure capacity across aging cardiovascular patient populations.

Structural Heart Devices Market Analysis by Age Group

Geriatrics contributes 50% share because structural cardiovascular disorders are concentrated across aging populations. Elderly patients increasingly prefer minimally invasive procedures due to lower recovery burden and reduced hospitalization periods.

• Elderly Cardiac Demand: Hospitals are increasing minimally invasive cardiac intervention programs across geriatric cardiovascular treatment operations.
• Recovery Efficiency Focus: Healthcare systems prefer transcatheter procedures because shorter recovery periods reduce post-procedure hospitalization pressure.
• Cardiovascular Screening Growth: Aging population expansion supports stronger diagnosis rates across aortic valve and congenital heart disorder treatment applications.

Structural Heart Devices Market Analysis by Indication

Aortic valve stenosis holds 45% share due to stronger transcatheter valve replacement concentration across stenosis treatment procedures. Cardiovascular specialists increasingly prefer minimally invasive intervention systems across elderly patients with severe stenosis conditions. Medtronic received U.S. FDA approval for its Evolut FX+ transcatheter aortic valve replacement system for symptomatic severe aortic stenosis. [3] The approval expands the company’s minimally invasive cardiovascular and structural heart intervention portfolio with advanced drug-coated catheter technology.

• Stenosis Treatment Expansion: Cardiac centers are increasing transcatheter aortic valve replacement capability across severe cardiovascular disease treatment operations.
• Clinical Procedure Adoption: Cardiologists are increasing minimally invasive valve intervention preference across high-risk surgical patient populations.
• Advanced Imaging Integration: Hospitals are increasing cardiac imaging investment across structural heart diagnosis and intervention planning systems.

Structural Heart Devices Market Analysis by End User

Hospitals account for 55% share because of stronger cardiovascular surgery infrastructure and advanced imaging capability. Large healthcare systems maintain higher structural heart intervention capacity compared with ambulatory surgical centers. Edwards Lifesciences expanded its structural heart business through the acquisitions of JenaValve Technology and Endotronix, strengthening its portfolio in transcatheter aortic valve replacement and heart failure monitoring technologies. [4] The strategic developments enhance Edwards’ capabilities in minimally invasive cardiovascular therapies and next-generation structural heart disease management solutions.

• Hospital Infrastructure Expansion: Multi-specialty hospitals are increasing catheterization laboratory investment across advanced cardiovascular treatment operations.
• Cardiac Center Development: Specialized cardiac centers are expanding minimally invasive intervention capability across structural heart procedure programs.
• Surgical Capacity Growth: Hospitals are increasing cardiovascular specialist recruitment and post-procedure monitoring infrastructure across tertiary healthcare facilities.

Drivers, Restraints, and Opportunities

Fact.MR analysts observe that structural heart intervention demand is increasing due to rising cardiovascular disease prevalence and expanding minimally invasive treatment preference. Hospitals are increasing investment across advanced cardiac surgery infrastructure due to stronger transcatheter intervention adoption and higher geriatric patient volume.

• Structural heart treatment demand is shifting toward catheter-based intervention systems across developed healthcare markets. Surgical valve procedures are losing relative share due to lower recovery efficiency and higher hospitalization burden. Boston Scientific announced the discontinuation of its ACURATE neo2 and ACURATE Prime transcatheter aortic valve replacement systems following increased regulatory and clinical requirements in global markets. [5] The decision reshapes competitive dynamics in the structural heart devices market, particularly within the minimally invasive TAVR segment.
• Minimally Invasive Procedure Shift: Hospitals are increasing transcatheter cardiovascular intervention adoption across structural heart treatment operations. Faster patient recovery supports higher hospital procedure turnover efficiency.
• Reimbursement Expansion: Public and private healthcare systems are increasing reimbursement coverage across minimally invasive cardiac intervention procedures. Broader insurance access supports higher hospital treatment volume.
• Asia Pacific Cardiac Investment: China and India are increasing specialized cardiovascular treatment infrastructure across tertiary healthcare systems. Higher cardiac diagnosis rates support stronger structural heart device demand.

Regional Analysis

The structural heart devices market is assessed across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa covering country level demand by product, procedure, indication, and healthcare infrastructure. The full report offers market attractiveness analysis by region and country.

Source: Fact.MR analysis, based on proprietary forecasting model and primary research

Asia Pacific Structural Heart Devices Market Analysis

Asia Pacific represents expanding cardiovascular intervention region due to rising hospital infrastructure investment and increasing cardiovascular disease burden. Domestic medical device manufacturers are increasing transcatheter system development capability across China and India.

• India: India is projected to expand at 13.1% CAGR supported by rising tertiary cardiac hospital investment and increasing transcatheter intervention adoption. Apollo Hospitals expanded structural heart intervention programs during 2025 across metropolitan cardiac treatment centers. Government healthcare expansion and rising cardiovascular diagnosis rates support stronger device procurement across private hospital systems.
• China: China records 12.6% CAGR attributable to domestic structural heart device manufacturing expansion and higher cardiovascular procedure volume. Lepu Medical increased transcatheter valve development activity during 2024 across cardiovascular device manufacturing operations. Rising urban healthcare investment and higher elderly population growth support stronger minimally invasive cardiac procedure demand.
• Japan: Japan is expected to register 9.1% CAGR due to rising geriatric cardiovascular treatment demand and advanced hospital imaging capability. Japanese healthcare systems are increasing minimally invasive cardiac procedure preference across elderly treatment programs. Aging population expansion supports stronger structural heart intervention requirement across regional healthcare networks.

North America Structural Heart Devices Market Analysis

North America represents leading structural heart intervention market supported by advanced hospital infrastructure and reimbursement coverage. Major cardiovascular device manufacturers maintain stronger positioning through physician training capability and broad hospital distribution networks. Higher adoption of minimally invasive procedures supports stronger transcatheter intervention growth across the region.

• United States: The United States is projected to grow at 11.4% CAGR driven by higher transcatheter valve replacement adoption and strong reimbursement coverage. Edwards Lifesciences expanded transcatheter valve training programs during 2025 across hospital cardiovascular centers. Medicare reimbursement support and rising elderly cardiovascular diagnosis rates strengthen structural heart device procedure volume.

Europe Structural Heart Devices Market Analysis

Europe represents a mature cardiovascular intervention market supported by advanced public healthcare systems and strong minimally invasive surgery adoption. Regional hospitals maintain high structural heart procedure capability across specialized cardiac treatment networks.

• Germany: Germany is projected to expand at 10.2% CAGR due to rising minimally invasive cardiac surgery preference and advanced tertiary hospital infrastructure. German cardiac centers are increasing transcatheter intervention programs across structural heart treatment operations. Public healthcare reimbursement and strong cardiovascular specialist availability support higher hospital procedure volume.

Latin America Structural Heart Devices Market Analysis

Latin America represents an expanding cardiovascular intervention market supported by rising private hospital investment and improving healthcare infrastructure. Structural heart treatment demand is concentrated across metropolitan healthcare systems due to stronger access to advanced cardiac surgery capability.

Brazil: Brazil is expected to register 9.8% CAGR supported by expanding private hospital cardiovascular intervention investment. Urban cardiac treatment centers are increasing minimally invasive structural heart procedure adoption across high income patient populations. Rising cardiovascular disease prevalence supports stronger transcatheter device procurement across regional healthcare systems.

Competitive Aligners for Market Players

The structural heart devices market is moderately concentrated around multinational cardiovascular device manufacturers and specialized intervention technology companies. Clinical evidence capability and physician training infrastructure shape competitive positioning across hospital procurement operations. Companies with advanced minimally invasive intervention portfolios maintain stronger pricing capability across tertiary healthcare systems.

Large cardiovascular device manufacturers maintain stronger positioning through reimbursement expertise and hospital distribution networks. Long term physician training partnerships improve clinical adoption across transcatheter procedure programs.

Integrated imaging compatibility and post-procedure support services strengthen hospital purchasing preference across structural heart intervention systems. Hospital procurement departments increasingly prefer suppliers with stable device performance data and broad cardiovascular product portfolios. Advanced transcatheter systems maintain higher pricing due to stronger clinical outcomes and lower surgical complication exposure. Medical device manufacturers are increasing investment across next-generation valve systems and minimally invasive cardiac repair technologies.

Key Players

• Abbott Laboratories, Inc.
• Boston Scientific Corporation
• CryoLife, Inc.
• Edwards Lifesciences Corporation
• Medtronic plc

Scope of the Report

Structural Heart Devices Market by Segment

• By Product:

  • Heart Valve Devices
  • Surgical Heart Valves
  • Transcatheter Heart Valves
  • Occluders & Delivery Systems

• By Procedure:

  • Replacement Procedures
  • Repair Procedures

• By Age Group:

  • Pediatrics
  • Adults
  • Geriatrics

• By Indication:

  • Atrial Septal Defect (ASD)
  • Ventricular Septal Defect (VSD)
  • Patent Foramen Ovale (PFO)
  • Aortic Valve Stenosis

• By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Cardiac Centers

• By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Latin America
    • Brazil
    • Argentina
    • Colombia
    • Rest of Latin America
  • Western Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Netherlands
    • Nordic Countries
    • BENELUX
    • Rest of Western Europe
  • East Asia
    • China
    • Japan
    • South Korea
  • South Asia and Pacific
    • India
    • ASEAN
    • Australia and New Zealand
    • Rest of South Asia and Pacific
  • Middle East and Africa
    • Kingdom of Saudi Arabia
    • Other GCC Countries
    • Turkey
    • South Africa
    • Rest of Middle East and Africa

Bibliography

• U.S. Food and Drug Administration. (2024). Edwards EVOQUE tricuspid valve replacement system - P230013. U.S. FDA. 
• Abbott Laboratories. (2024). Abbott receives FDA approval for TriClip™, first-of-its-kind device to repair leaky tricuspid heart valve. Abbott MediaRoom. 
• Medtronic. (2024). Medtronic announces FDA approval of Evolut FX+ TAVR system for symptomatic severe aortic stenosis. Medtronic Newsroom. 
• Diagnostic and Interventional Cardiology. (2024). Edwards Lifesciences expands structural heart portfolio with acquisitions of JenaValve and Endotronix. Diagnostic and Interventional Cardiology. 
• Cardiovascular Intervention Today. (2024). Boston Scientific discontinues ACURATE neo2 and ACURATE Prime TAVR systems. Cardiovascular Intervention Today.

This Report Addresses

•  Analysis of structural heart intervention demand across product type and hospital treatment applications.
•  Market forecast from USD 16.7 billion in 2026 to USD 48.2 billion by 2036 at 11.2% CAGR.
• Growth assessment across India, China, the United States, and Germany linked with cardiovascular intervention expansion.
• Segment analysis across product, procedure, and indication with 2026 share benchmarks and regional forecasts.
• Competitive analysis of Edwards Lifesciences, Abbott Laboratories, Boston Scientific, and major cardiovascular device manufacturers.
•  Regulatory and reimbursement analysis covering minimally invasive cardiac intervention adoption across healthcare systems.
• Report available with cardiovascular procedure and hospital procurement analysis.

Structural Heart Devices Market Definition

Structural heart devices are implantable medical systems used for treatment of congenital and acquired heart valve and cardiac wall disorders. These devices include transcatheter valves, occluders, repair systems, and surgical valve implants used across minimally invasive and open heart procedures. Hospitals and cardiac centers use these products to treat aortic stenosis, atrial septal defect, ventricular septal defect, and other structural cardiac conditions.

Structural Heart Devices Market Inclusions

The study covers global and regional forecasts from 2026 to 2036 by product, procedure, age group, indication, and end user. The report includes structural heart implant demand analysis, transcatheter procedure trends, cardiac intervention pricing analysis, and hospital adoption patterns across developed and emerging healthcare markets.

Structural Heart Devices Market Exclusions

The study excludes coronary stents, pacemakers, cardiac rhythm management systems, and pharmaceutical cardiovascular therapies. General cardiac monitoring devices and external diagnostic systems are outside the defined scope unless directly integrated with structural heart intervention procedures.

Structural Heart Devices Market Research Methodology

• Primary Research
  • Interviews with cardiac surgeons, interventional cardiologists, hospital procurement departments, ambulatory surgical center administrators, and structural heart device manufacturers across the United States, China, India, Germany, Brazil, and Japan.
• Desk Research
  • Analysis of Edwards Lifesciences, Abbott Laboratories, Boston Scientific, Medtronic, and Lepu Medical announcements along with FDA and CE approval updates released during 2024 and 2025.
• Market-Sizing and Forecasting
  • Hybrid top-down and bottom-up model using cardiovascular procedure volume analysis, hospital device procurement trends, reimbursement assessment, and primary interviews with cardiac device manufacturers and healthcare providers.
• Data Validation and Update Cycle
  • Outputs were validated through hospital purchasing records, regulatory approval databases, distributor interviews, and cardiovascular procedure volume analysis. Estimates were reconciled against device shipment trends and public company disclosures.